8legs: Glaxosmithkline

Your Followed Topics

#1 out of 2

Branscome led the growth of the Los Angeles office to more than 30 lawyers within her first year.
She directed defense strategy for GSK in thousands of cancer-related claims.
Branscome served as lead trial counsel for Johnson & Johnson in talcum-based litigation.
Her wildfire response helped Pacific Palisades neighbors with insurance recovery efforts.
Her courtroom impact included defense verdicts in a Monsanto PCB trial.
The profile places Branscome among leaders shaping Southern California civil rights litigation.
Her work spans mass torts, product liability, and high-stakes litigation.
Branscome has a background in handling defense strategies for multinational clients.
Her leadership influenced both litigation outcomes and firm growth in a competitive market.
The piece situates Branscome within ongoing discussions about legal strategy and community impact.

Vote 0

#2 out of 2100.00%

GSK plans a portfolio event to discuss Q2 results and HIV patent-cliff strategy.
Summit will test its PD-1/VEGF bispecific with GSK’s B7-H3 ADC across solid tumors.
The collaboration targets small cell lung cancer among other solid tumors.
TradingView notes potential exclusivity losses tied to HIV patent issues.
GSK expects Phase III trials to begin as part of its strategy.
Mergers and acquisitions activity around GSK could offset losses.
The news center on GSK’s strategy amid HIV patent cliff pressures.
The collaboration includes ivonescimab with risvutatug rezetecan across solid tumors.
The report emphasizes ongoing trials and collaboration as core to the plan.
The coverage originates from TradingView News and summarizes key facts.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.